The gut microbiota-host partnership as a potential driver of Kawasaki syndrome

Frontiers in Pediatrics

Volumn 7, Issue APR, 2019, Pages

  Esposito, Susanna ^a   Polinori, Ilaria ^a   Rigante, Donato ^b,c,d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Child; Infection; Innovative biotechnologies; Kawasaki syndrome; Microbiota; Personalized medicine

Indexed keywords

ARTICLE; BACTERIAL FLORA; CHILDHOOD DISEASE; HUMAN; INFECTION; INTESTINE FLORA; MEDLINE; MICROBIAL COMMUNITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN;

EID: 85064641306     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2019.00124     Document Type: Article

References (97)

1. Chang LY, Lu CY, Shao PL, Lee PI, Lin MT, Fan TY, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc. (2014) 113:148-54. doi: 10.1016/j.jfma.2013.12.008
2. Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr. (2018) 6:198. doi: 10.3389/fped.2018.00198
3. Sehgal S, Chen X, Ang JY. Epidemiology, clinical presentation, and outcomes of Kawasaki disease among hospitalized children in an inner city hospital before and after publication of the American Academy of Pediatrics/American Heart Association Guidelines for treatment of Kawasaki disease: an 11-year period. Clin Pediatr. (2015) 54:1283-9. doi: 10.1177/0009922815592877
4. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. (1974) 54:271-6.
5. Marchesi A, Tarissi de Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I-definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr. (2018) 44:102. doi: 10.1186/s13052-018-0536-3
6. Marchesi A, Tarissi de Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II-treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr. (2018) 44:103. doi: 10.1186/s13052-018-0529-2
7. De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. (2007) 11:301-8.
8. Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int. (2010) 30:841-6. doi: 10.1007/s00296-009-1337-1
9. Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S. Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. Int J Mol Sci. (2016) 17:278. doi: 10.3390/ijms17030278
10. Hall GC, Tulloh LE, Tulloh RM. Kawasaki disease incidence in children and adolescents: an observational study in primary care. Br J Gen Pract. (2016) 66:271-6. doi: 10.3399/bjgp16X684325
11. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-10 nationwide survey. J Epidemiol. (2012) 22:216-21. doi: 10.2188/jea.JE20110126
12. Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the aetiology? Int J Infect Dis. (2005) 9:185-94. doi: 10.1016/j.ijid.2005.03.002
13. Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. J Infect. (2013) 67:1-10. doi: 10.1016/j.jinf.2013.04.004
14. Robinson CM, Pfeiffer JK. Viruses and the microbiota. Annu Rev Virol. (2014) 1:55-69. doi: 10.1146/annurev-virology-031413-085550
15. Sudo D, Nakamura Y. Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatr. (2017) 106:796-800. doi: 10.1111/apa.13773
16. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. (2015) 17:690-703. doi: 10.1016/j.chom.2015.04.004
17. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA. (2011) 108:4578-85. doi: 10.1073/pnas.1000081107
18. Buccigrossi V, Nicastro E, Guarino A. Functions of intestinal microflora in children. Curr Opin Gastroenterol. (2013) 29:31-8. doi: 10.1097/MOG.0b013e32835a3500
19. Palmer C, Bik EM, Di Giulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. (2007) 5:e177. doi: 10.1371/journal.pbio.0050177
20. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. (2011) 473:174-80. doi: 10.1038/nature09944
21. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. (2011) 334:105-8. doi: 10.1126/science.1208344
22. Chen J, Ryu E, Hathcock M, Ballman K, Chia N, Olson JE, et al. Impact of demographics on human gut microbial diversity in a US Midwest population. Peer J. (2016) 4:1514. doi: 10.7717/peerj.1514
23. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. (2009) 457:480-4. doi: 10.1038/nature07540
24. Dekio I, Hayashi H, Sakamoto M, Kitahara M, Nishikawa T, Suematsu M, et al. Detection of potentially novel bacterial components of the human skin microbiota using culture-independent molecular profiling. J Med Microbiol. (2005) 54:1231-8. doi: 10.1099/jmm.0.46075-0
25. Sakata S, Tonooka T, Ishizeki S, Takada M, Sakamoto M, Fukuyama M, et al. Culture-independent analysis of fecal microbiota in infants, with special reference to Bifidobacterium species. FEMS Microbiol Lett. (2005) 243:417-23. doi: 10.1016/j.femsle.2005.01.002
26. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. (2010) 330:1768-73. doi: 10.1126/science.1195568
27. Candela M, Rampelli S, Turroni S, Severgnini M, Consolandi C, de Bellis G, et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiol. (2012) 12:95. doi: 10.1186/1471-2180-12-95
28. Siogren YM, Jenmalm MC, Botcher MF, Bjrksten B, Sverremark-Ekstrom E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy. (2009) 39:518-26. doi: 10.1111/j.1365-2222.2008.03156.x
29. Aguilera M, Cerdà-Cuéllar M, Martínez V. Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes. (2015) 6:10-23. doi: 10.4161/19490976.2014.990790
30. Davies JM, Abreu MT. Host microbe interactions in the small bowel. Curr Opin Gastroenterol. (2015) 31:118-23. doi: 10.1097/MOG.0000000000000143
31. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. (2012) 486:207-14. doi: 10.1038/nature11234
32. Alexander KL, Targan SR, Elson CO. Microbiota activation and regulation of innate and adaptative immunity. Immunol Rev. (2014) 260:206-20. doi: 10.1111/imr.12180
33. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr. (2010) 157:240-4. doi: 10.1016/j.jpeds.2010.02.046
34. De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. (2010) 10:63. doi: 10.1186/1471-2180-10-63
35. Schippa S, Iebba V, Barbato M, Di Nardo G, Totino V, Checchi MP, et al. A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiol. (2010) 10:175. doi: 10.1186/1471-2180-10-175
36. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. (2001) 48:206-11. doi: 10.1136/gut.48.2.206
37. Rigante D, Vitale A, Cantarini L. Autoinflammatory diseases. In: Ragab G, Atkinson TP, Stoll ML, editors. The Microbiome in Rheumatic Diseases and Infection. Cham: Springer International Publishing (Springer Nature) (2018). p. 371-7. doi: 10.1007/978-3-319-79026-8_28
38. Rigante D. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. Expert Rev Clin Immunol. (2017) 13:571-97. doi: 10.1080/1744666X.2017.1280396
39. Rigante D. A developing portrait of hereditary periodic fevers in childhood. Expert Opin Orphan Drugs. (2018) 6:47-55. doi: 10.1080/21678707.2018.1406797
40. Rigante D. The broad-ranging panorama of systemic autoinflammatory disorders with specific focus on acute painful symptoms and hematologic manifestations in children. Mediterr J Hematol Infect Dis. (2018) 10:e2018067. doi: 10.4084/mjhid.2018.067
41. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J. (2011) 9:17. doi: 10.1186/1546-0096-9-17
42. Rigante D, Tarantino G, Valentini P. Non-infectious makers of Kawasaki syndrome: tangible or elusive triggers? Immunol Res. (2016) 64:51-4. doi: 10.1007/s12026-015-8679-4
43. Rowley AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis. (2018) 21:20-5. doi: 10.1111/1756-185X.13213
44. Nakamura Y. Kawasaki disease: epidemiology and the lessons from it. Int J Rheum Dis. (2018) 21:16-9. doi: 10.1111/1756-185X.13211
45. Burns JC, Glode MP. Kawasaki syndrome. Lancet. (2004) 364:533-44. doi: 10.1016/S0140-6736(04)16814-1
46. Andreozzi L, Bracci B, D'Errico F, Rigante D. A master role for neutrophils in Kawasaki syndrome. Immunol Lett. (2017) 184:112-4. doi: 10.1016/j.imlet.2017.02.011
47. Manlhiot C, Mueller B, O'Shea S, Majeed H, Bernknopf B, Labelle M, et al. Environmental epidemiology of Kawasaki disease: linking disease etiology, pathogenesis and global distribution. PLoS ONE. (2018) 13:e0191087. doi: 10.1371/journal.pone.0191087
48. Takeshita S, Tsujimoto H, Kawase H, Kawamura Y, Sekine I. Increased levels of lipopolysaccharide binding protein in plasma in children with Kawasaki disease. Clin Diagn Lab Immunol. (2002) 9:205-6. doi: 10.1128/CDLI.9.1.205-206.2002
49. Chen Y, Li X, Boini KM, Pitzer AL, Gulbins E, Zhang Y, et al. Endothelial NLRP3 inflammasome activation associated with lysosomal destabilization during coronary arteritis. Biochim Biophys Acta. (2015) 1853:396-408. doi: 10.1016/j.bbamcr.2014.11.012
50. Xia M, Boini KM, Abais JM, Xu M, Zhang Y, Li PL. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol. (2014) 184:1617-28. doi: 10.1016/j.ajpath.2014.01.032
51. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol. (1997) 159:481-6.
52. Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genom. (2015) 16:1076. doi: 10.1186/s12864-015-2323-5
53. Alexoudi I, Kanakis M, Kapsimali V, Vaiopoulos G. Kawasaki disease: current aspects on aetiopathogenesis and therapeutic management. Autoimmun Rev. (2011) 10:544-7. doi: 10.1016/j.autrev.2011.04.005
54. Rowley AH, Baker SC, Shulman ST, Rand KH, Tretiakova MS, Perlman EJ, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis. (2011) 203:1021-30. doi: 10.1093/infdis/jiq136
55. Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE. (2008) 3:1582. doi: 10.1371/journal.pone.0001582
56. Rowley AH, Baker SC, Shulman ST, Fox LM, Takahashi K, Garcia FL, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis. (2005) 192:1757-66. doi: 10.1086/497171
57. Rowley AH, Eckerley CA, Jäck HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol. (1997) 159:5946-55.
58. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics. (2015) 136:609-14. doi: 10.1542/peds.2015-0950
59. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. (2005) 191:499-502. doi: 10.1086/428291
60. Shimizu C, Shike H, Baker SC, Garcia F, van der Hoek L, Kuijpers TW, et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. J Infect Dis. (2005) 192:1767-71. doi: 10.1086/497170
61. Chua PK, Nerurkar VR, Yu Q, Woodward CL, Melish ME, Yanagihara R. Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpes-virus 8, TT virus, GB virus C/hepatitis G virus or Chlamydia pneumoniae. Pediatr Infect Dis J. (2000) 19:477-9. doi: 10.1097/00006454-200005000-00019
62. Kanegane H, Tsuji T, Seki H, Yachie A, Yokoi T, Miyawaki T, et al. Kawasaki disease with a concomitant primary Epstein-Barr virus infection. Acta Paediatr Jpn. (1994) 36:713-6. doi: 10.1111/j.1442-200X.1994.tb03277.x
63. Embil JA, McFarlane ES, Murphy DM, Krause VW, Stewart HB. Adenovirus type 2 isolated from a patient with fatal Kawasaki disease. Can Med Assoc J. (1985) 132:1400.
64. Hagiwara K, Komura H, Kishi F, Kaji T, Yoshida T. Isolation of human herpesvirus-6 from an infant with Kawasaki disease. Eur J Pediatr. (1992) 152:176. doi: 10.1007/BF02072502
65. Kuijpers TW, Herweijer TJ, Scholvinck L, Wertheim-Van Dillen PM, Van De Veer EM. Kawasaki disease associated with measles virus infection in a monozygotic twin. Pediatr Infect Dis J. (2000) 19:350-3. doi: 10.1097/00006454-200004000-00018
66. Johnson D, Azimi P. Kawasaki disease associated with Klebsiella pneumoniae bacteremia and parainfluenza type 3 virus infection. Pediatr Infect Dis J. (1985) 4:100. doi: 10.1097/00006454-198501000-00024
67. Sopontammarak S, Pruekprasert P. Concomitant dengue hemorrhagic fever with Kawasaki disease. Southeast Asian J Trop Med Public Health. (2000) 31:190-2.
68. Joshi AV, Jones KD, Buckley AM, Coren ME, Kampmann B. Kawasaki disease coincident with influenza A H1N1/09 infection. Pediatr Int. (2011) 53:e1-2. doi: 10.1111/j.1442-200X.2010.03280.x
69. Rigante D, Cantarini L, Piastra M, Angelone DF, Valentini P, Pardeo M, et al. Kawasaki syndrome and concurrent Coxsackie-virus B3 infection. Rheumatol Int. (2012) 32:4037-40. doi: 10.1007/s00296-010-1613-0
70. Song E, Kajon AE, Wang H, Salamon D, Texter K, Ramilo O, et al. Clinical and virologic characteristics may aid distinction of acute adenovirus disease from Kawasaki disease with incidental adenovirus detection. J Pediatr. (2016) 170:325-30. doi: 10.1016/j.jpeds.2015.11.021
71. Jaggi P, Kajon AE, Mejias A, Ramilo O, Leber A. Human adenovirus infection in Kawasaki disease: a confounding bystander? Clin Infect Dis. (2013) 56:58-64. doi: 10.1093/cid/cis807
72. Usta Guc B, Cengiz N, Yildirim SV, Uslu Y. Cytomegalovirus infection in a patient with atypical Kawasaki disease. Rheumatol Int. (2008) 28:387-9. doi: 10.1007/s00296-007-0440-4
73. Bajolle F, Meritet JF, Rozenberg F, Chalumeau M, Bonnet D, Gendrel D, et al. Markers of a recent bocavirus infection in children with Kawasaki disease: "A year prospective study". Pathol Biol. (2014) 62:365-8. doi: 10.1016/j.patbio.2014.06.002
74. Yoshioka T, Matsutani T, Iwagami S, Toyosaki-Maeda T, Yutsudo T, Tsuruta Y, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology. (1999) 96:465-72. doi: 10.1046/j.1365-2567.1999.00695.x
75. Leung DYM, Meissner HC, Shulman ST, Mason WH, Gerber MA, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr. (2002) 140:742-6. doi: 10.1067/mpd.2002.123664
76. Matsubara K, Fukaya T, Miwa K, Shibayama N, Nigami H, Harigaya H, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol. (2006) 143:427-34. doi: 10.1111/j.1365-2249.2006.03015.x
77. Matsubara K, Fukaya T. The role of superantigens of group A Streptococcus and Staphylococcus aureus in Kawasaki disease. Curr Opin Infect Dis. (2007) 20:298-303. doi: 10.1097/QCO.0b013e3280964d8c
78. Suenaga T, Suzuki H, Shibuta S, Takeuchi T, Yoshikawa N. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr. (2009) 155:266-70. doi: 10.1016/j.jpeds.2009.03.013
79. Lee MN, Cha JH, Ahn HM, Yoo JH, Kim HS, Sohn S, et al. Mycoplasma pneumoniae infection in patients with Kawasaki disease. Korean J Pediatr. (2011) 54:123-7. doi: 10.3345/kjp.2011.54.3.123
80. Rodo X, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci USA. (2014) 111:7952-7. doi: 10.1073/pnas.1400380111
81. Sato W, Ishibashi KI, Yamanaka D, Adachi Y, Ohno N. Effects of natural and chemically defined nutrients on Candida albicans water-soluble fraction (CAWS) vasculitis in mice. Med Mycol J. (2017) 58:E47-62. doi: 10.3314/mmj.16-00014
82. Ishida-Okawara A, Nagi-Miura N, Oharaseki T, Takahashi K, Okumura A, Tachikawa H, et al. Neutrophil activation and arteritis induced by C. albicans water-soluble mannoprotein-beta-glucan complex (CAWS). Exp Mol Pathol. (2007) 82:220-6. doi: 10.1016/j.yexmp.2006.05.006
83. Nagi-Miura N, Shingo Y, Adachi Y, Ishida-Okawara A, Oharaseki T, Takahashi K, et al. Induction of coronary arteritis with administration of CAWS (Candida albicans water-soluble fraction) depending on mouse strains. Immunopharmacol Immunotoxicol. (2004) 26:527-43. doi: 10.1081/IPH-200042295
84. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. Med Hypotheses. (2007) 69:642-51. doi: 10.1016/j.mehy.2006.12.051
85. Horita N, Yokota S, Fuse S, Takamuro M, Tomita H, Sato K, et al. The throat flora and its mitogenic activity in patients with Kawasaki disease. Microbiol Immunol. (2004) 48:899-903. doi: 10.1111/j.1348-0421.2004.tb03609.x
86. Yamashiro Y, Nagata S, Ohtsuka Y, Oguchi S, Shimizu T. Microbiologic studies on the small intestine in Kawasaki disease. Pediatr Res. (1996) 39:622-4. doi: 10.1203/00006450-199604000-00010
87. Nagata S, Yamashiro Y, Maeda M, Ohtsuka Y, Yabuta K. Immunohistochemical studies on small intestinal mucosa in Kawasakidisease. Pediatr Res. (1993) 33:557-63. doi: 10.1203/00006450-199306000-00004
88. Eladawy M, Dominguez SR, Anderson MS, Glodé MP. Kawasaki disease and the pediatric gastroenterologist: a diagnostic challenge. J Pediatr Gastroenterol Nutr. (2013) 56:297-99. doi: 10.1097/MPG.0b013e3182794432
89. Takeshita S, Kobayashi I, Kawamura Y, Tokutomi T, Sekine I. Characteristic role of intestinal microflora in Kawasaki disease. Acta Pediatr. (2001) 91:783-88. doi: 10.1111/j.1651-2227.2002.tb03327.x
90. Reading NC, Kasper DL. The starting lineup: key microbial players in intestinal immunity and homeostasis. Front Microbiol. (2011) 2:148. doi: 10.3389/fmicb.2011.00148
91. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. (2011) 60:1050-9. doi: 10.1136/gut.2010.232918
92. Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppée JY, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. (2006) 176:1228-37. doi: 10.4049/jimmunol.176.2.1228
93. Nagata S, Yamashiro Y, Ohtsuka Y, Shimizu T, Sakurai Y, Misawa S, et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. Immunology. (2009) 12:511-20. doi: 10.1111/j.1365-2567.2009.03135.x
94. Kinumaki A, Sekizuka T, Hamada H, Kato K, Yamashita A, Kuroda M. Characterization of the gut microbiota of Kawasaki disease patients by metagenomic analysis. Front Microbiol. (2015) 6:824. doi: 10.3389/fmicb.2015.00824
95. De Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep. (2016) 6:23561. doi: 10.1038/srep23561
96. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. (2014) 513:59-64. doi: 10.1038/nature13568
97. Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: the two sides of the microbiota. N Microbiol. (2016) 39:1-12.